RIGL Company Profile and Key Details

Q: Who are the executives of RIGL?

Dr. Esteban S. MasudaExecutive Vice President of ResearchMr. Tarek SallamVice President of MarketingDr. Wolfgang Dummer M.D., Ph.D.Executive Vice President & Chief Medical OfficerMr. Dean L. Schorno C.P.A.Executive Vice President & Chief Financial OfficerMr. Raul R. RodriguezPres, Chief Executive Officer & DirectorMr. Dean L. Schorno CPAExecutive Vice President & Chief Financial OfficerMr. Raymond J. Furey J.D.Executive Vice President, Gen. Counsel & Corporation Sec.Mr. David A. SantosExecutive Vice President & Chief Commercial OfficerMr. Joseph LasagaExecutive Vice President of Corporation Devel.Ms. Julie PatelSenior Vice President of HR

NASDAQ : RIGL

Rigel Pharmaceuticals

$28.90

-0.32-1.10%

At Close 4:00 PM

61.6

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Rigel Pharmaceuticals, Inc. (RIGL) stock surged +1.73%, trading at $29.40 on NASDAQ, up from the previous close of $28.90. The stock opened at $29.01, fluctuating between $28.79 and $29.59 in the recent session.

Stock Snapshot

28.9

Prev. Close

543.31M

Market Cap

28.79

Day Low

1.51

P/E Ratio

19.48

EPS (TTM)

-0.12

Cash Flow per Share

29.01

Open

18.48M

Number of Shares

29.59

Day High

89.67%

Free Float in %

-0.16

Book Value

177.72K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	29.49	29.98	28.59	28.90	440.94K
Apr 29, 2026	30.10	30.41	29.01	29.22	265.1K
Apr 28, 2026	30.69	31.35	30.47	30.56	309.41K
Apr 27, 2026	30.24	30.90	30.20	30.51	195.05K
Apr 23, 2026	30.57	30.89	29.89	30.72	178.64K
Apr 22, 2026	32.45	32.78	30.20	30.47	522.35K
Apr 21, 2026	32.49	32.71	32.00	32.29	244.48K
Apr 20, 2026	32.41	33.10	32.01	32.49	235.71K
Apr 17, 2026	32.80	33.17	32.00	32.43	418.08K
Apr 16, 2026	32.28	32.28	31.25	31.77	413.79K
Apr 14, 2026	30.45	31.46	30.31	31.39	412.87K
Apr 13, 2026	29.01	30.25	28.83	29.97	284.59K
Apr 10, 2026	30.55	30.55	28.78	29.20	740.76K
Apr 09, 2026	29.30	30.61	29.08	30.51	368.08K
Apr 08, 2026	29.52	29.91	28.45	29.73	385.37K
Apr 07, 2026	26.94	28.75	26.90	28.73	470.8K
Apr 06, 2026	27.58	27.95	27.13	27.36	202.5K
Apr 02, 2026	26.83	27.62	26.75	27.53	186.46K
Apr 01, 2026	27.35	28.23	27.10	27.50	246.67K
Mar 31, 2026	26.27	27.17	26.27	27.04	208.91K

Contact Details

South San Francisco, CA 94080

United States

https://www.rigel.com 650 624 1100

About Company

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) closed at $29.40 USD, gaining $0.50 (1.73%) from the previous close of $28.90. The stock is currently mid-range between its 52-week high and low $16.88 and $52.24. With a market capitalization of about $543.31 million, Rigel Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.27). Key stats such as the average daily volume over the past year has been around 348.90 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Rigel Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raul R. Rodriguez, the company employs approximately 162 people and listed since November 29, 2000. Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 2.1%, SMA50 -7.21%, SMA200 11.44%). The stock’s 14-day RSI is 48.35 (neutral), while the ATR of 1.68 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.64% below its high and over 130.39% above its low. Average 10-day trading volume of 318.58 thousand shares is in line with the 3-month average of 325.06 thousand, indicating normal recent market interest.

Valuation Metrics

Rigel Pharmaceuticals, Inc. trades at a P/E ratio of 1.42, slightly below the S&P 500 average, with a price-to-sales ratio of 1.81 and a price-to-book ratio of 1.33 suggesting the stock is closer to book value. The P/FCF stands at 7.06, also above market averages.

Dividend & Fair Value

Rigel Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$31.01. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 67.79% annually over the next five years. The latest quarter delivered EPS of $1.14. The next quarter is forecast at $1.20. Next year's EPS is expected at $60.82. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $57.00 to $32.00. The high target offers 97.23% upside. The low target suggests 10.73% downside. The mean target is $42.25. This offers 46.19% upside. Rigel Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 03, 2026, missed forecasts by -14.29%. The prior quarter beat by 56.99%. Over the last six quarters, Apple has recorded several small beats. These include 1066.67% in November 07, 2024.

Shareholding & Insider Activity

Rigel Pharmaceuticals, Inc. has 17.94 million shares outstanding. The public float is 16.08 million shares, elevated short interest at 11.37% of float. This equals 1.99 million shares. The short ratio is 3.52 days. Institutional investors hold 92.97% of the float. Insiders own 3.07%. BVF PARTNERS L P/IL holds 646.56 thousand shares, Flynn James E has 470.42 thousand shares and RODRIGUEZ RAUL R has 239.45 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.00 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Rigel Pharmaceuticals generated $116.88M in revenue, or $0.67 per share. Gross margin was 93.92%, operating margin -17.53%, and net profit margin -21.47%. Returns are negative, with ROA at -21.40% and ROE at 87.60%.
On valuation metrics, Rigel Pharmaceuticals trades at a P/E of 1.42, P/S of 1.81 and P/B of 1.33. The current ratio is 2.42 and quick ratio is 2.30. Operationally, the company’s inventory turnover is 1.71 and cash conversion cycle is 144.47 days. Debt-to-equity is 0.14, supported by a cash flow-to-debt ratio of 1.42.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Rigel Pharmaceuticals posted revenue of $116.88M, down slightly from $120.24M in the prior quarter. Gross profit was $109.77M (margin 93.92%). Operating income was - $20.49M (margin -17.5%). Net income was- $25.09M (EPS - $0.14).
The company ended the quarter with $56.93M in cash and short-term investments, a total debt of $60.58M, and net debt of $27.79M. Total assets were $117.23M, with equity of - $28.64M. Financials further reflected weakness, with operating cash flow of - $5.74M, free cash flow of - $20.74M, and capital expenditures of - $15.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Rigel Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.2%, with price expected at $31.56 by May 14, 2026, within a range of $30.24 to $32.88 3-Month Outlook: Projected rise of 36.85%, reaching $39.55 by July 29, 2026, with a range of $37.15 to $41.87. 1-Year Outlook: Projected gain of 32.73%, with price at $38.36 by April 30, 2027, within a range of $36.28 to $40.85.

Key Takeaways

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares are down -15.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Rigel Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 1.42. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $23.08, suggesting -20.14% downside. Our AI forecast model points to short-term strength (9.2% over two weeks), a medium-term rise (36.85% over three months), and a longer-term gain (32.73% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Rigel Pharmaceuticals, Inc. (RIGL) stock price?

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) stock price is $29.40 in the last trading session. During the trading session, RIGL stock reached the peak price of $29.59 while $28.79 was the lowest point it dropped to. The percentage change in RIGL stock occurred in the recent session was 1.73% while the dollar amount for the price change in RIGL stock was $0.50.

RIGL's industry and sector of operation?

The NASDAQ listed RIGL is part of Biotechnology industry that operates in the broader Healthcare sector. Rigel Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RIGL?

Dr. Esteban S. Masuda
Executive Vice President of Research
Mr. Tarek Sallam
Vice President of Marketing
Dr. Wolfgang Dummer M.D., Ph.D.
Executive Vice President & Chief Medical Officer
Mr. Dean L. Schorno C.P.A.
Executive Vice President & Chief Financial Officer
Mr. Raul R. Rodriguez
Pres, Chief Executive Officer & Director
Mr. Dean L. Schorno CPA
Executive Vice President & Chief Financial Officer
Mr. Raymond J. Furey J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. David A. Santos
Executive Vice President & Chief Commercial Officer
Mr. Joseph Lasaga
Executive Vice President of Corporation Devel.
Ms. Julie Patel
Senior Vice President of HR

How RIGL did perform over past 52-week?

RIGL's closing price is 71.21% higher than its 52-week low of $16.88 where as its distance from 52-week high of $52.24 is -44.68%.

How many employees does RIGL have?

Number of RIGL employees currently stands at 162.

Link for RIGL official website?

Official Website of RIGL is: https://www.rigel.com

How do I contact RIGL?

RIGL could be contacted at phone 650 624 1100 and can also be accessed through its website. RIGL operates from 1180 Veterans Boulevard, South San Francisco, CA 94080, United States.

How many shares of RIGL are traded daily?

RIGL stock volume for the day was 177.72K shares. The average number of RIGL shares traded daily for last 3 months was 348.9K.

What is the market cap of RIGL currently?

The market value of RIGL currently stands at $543.31M with its latest stock price at $29.40 and 18.48M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	162
Beta	1.27
Sales or Revenue	$116.88M
5Y Sales Change%	1.422%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RIGL Company Profile and Key Details

Rigel Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways